Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug–carrier interactions

2011 ◽  
Vol 8 (3) ◽  
pp. 329-342 ◽  
Author(s):  
Katarzyna Kita ◽  
Christian Dittrich
2019 ◽  
Vol 20 (2) ◽  
pp. 315 ◽  
Author(s):  
Eun Kang ◽  
Yu Baek ◽  
Eunil Hahm ◽  
Sang Lee ◽  
Xuan-Hung Pham ◽  
...  

Cyclodextrins (CDs) have beneficial characteristics for drug delivery, including hydrophobic interior surfaces. Nanocarriers with β-CD ligands have been prepared with simple surface modifications as drug delivery vehicles. In this study, we synthesized β-CD derivatives on an Ag-embedded silica nanoparticle (NP) (SiO2@Ag NP) structure to load and release doxorubicin (DOX). Cysteinyl-β-CD and ethylenediamine-β-CD (EDA-β-CD) were immobilized on the surface of SiO2@Ag NPs, as confirmed by transmission electron microscopy (TEM), ultraviolet-visible (UV-Vis) spectrophotometry, and Fourier transform infrared (FTIR) spectroscopy. DOX was introduced into the β-CD on the SiO2@Ag NPs and then successfully released. Neither cysteinyl-β-CD and EDA-β-CD showed cytotoxicity, while DOX-loaded cysteinyl-β-CD and EDA-β-CD showed a significant decrease in cell viability in cancer cells. The SiO2@Ag NPs with β-CD provide a strategy for designing a nanocarrier that can deliver a drug with controlled release from modified chemical types.


2021 ◽  
Vol 1 (1) ◽  
pp. 30-43
Author(s):  
Mostafa Yusefi ◽  
Kamyar Shameli

With the high demand of using nanotechnology, nanocellulose has become popular for different biomedical and anticancer applications. Cellulose, a nature gifted material and the most abundant organic polymer on earth, is systematically reviewed. Details of the mechanical and chemical structure of nanocellulose are explained, starting with preparation methods along with physiochemical properties and pH gradient to incorporate innovative polymeric drug delivery vehicles in anticancer applications. A myriad of research fields has introduced nanocellulose as an intriguing candidate for anticancer drug excipient and carrier in modern cancer therapy. Albeit, innovative nanocellulose-based drug carrier systems will be complicated for their commercial use in pharmacies. Of this, it is required to understand the preparation, properties, and potential drug conjugation of nanocellulose to improve its interactions with human tissues.


ACS Nano ◽  
2014 ◽  
Vol 8 (2) ◽  
pp. 1525-1537 ◽  
Author(s):  
Vipul Gujrati ◽  
Sunghyun Kim ◽  
Sang-Hyun Kim ◽  
Jung Joon Min ◽  
Hyon E Choy ◽  
...  

2014 ◽  
Vol 50 (37) ◽  
pp. 4827-4830 ◽  
Author(s):  
Miao Yang ◽  
Dawei Xu ◽  
Linhai Jiang ◽  
Lin Zhang ◽  
Derek Dustin ◽  
...  

We report here a facile approach to prepare filamentous supramolecular peptide–drug conjugates with precise drug/carrier stoichiometry, nearly 100% loading efficiency and exceptional anti-cancer drug efficacy for chemotherapy.


Nanomedicine ◽  
2020 ◽  
Vol 15 (27) ◽  
pp. 2707-2727
Author(s):  
Filippo Pinelli ◽  
Óscar Fullana Ortolà ◽  
Pooyan Makvandi ◽  
Giuseppe Perale ◽  
Filippo Rossi

In recent years, nanogels have emerged as promising drug delivery vehicles; their ability in holding active molecules, macromolecules and drugs, together with the capability to respond to external stimuli, makes them a suitable tool for a wide range of applications. These features allow nanogels to be exploited against many challenges of nanomedicine associated with different kinds of pathologies which require the use of specific drug delivery systems. In this review our aim is to give the reader an overview of the diseases that can be treated with nanogels as drug delivery systems, such as cancer, CNS disorders, cardiovascular diseases, wound healing and other diseases of human body. For all of these pathologies, biological in vivo assays can be found in the literature and in this work. We focus on the peculiarities of these nanogels, highlighting their features and their advantages in respect to conventional treatments.


2018 ◽  
Vol 18 (5) ◽  
pp. 439-457 ◽  
Author(s):  
Merina Mariyam ◽  
Kajal Ghosal ◽  
Sabu Thomas ◽  
Nandakumar Kalarikkal ◽  
Mahima S. Latha

2020 ◽  
Vol 17 (3) ◽  
pp. 229-245
Author(s):  
Gang Wang ◽  
Junjie Wang ◽  
Rui Guan

Background: Owing to the rich anticancer properties of flavonoids, there is a need for their incorporation into drug delivery vehicles like nanomicelles for safe delivery of the drug into the brain tumor microenvironment. Objective: This study, therefore, aimed to prepare the phospholipid-based Labrasol/Pluronic F68 modified nano micelles loaded with flavonoids (Nano-flavonoids) for the delivery of the drug to the target brain tumor. Methods: Myricetin, quercetin and fisetin were selected as the initial drugs to evaluate the biodistribution and acute toxicity of the drug delivery vehicles in rats with implanted C6 glioma tumors after oral administration, while the uptake, retention, release in human intestinal Caco-2 cells and the effect on the brain endothelial barrier were investigated in Human Brain Microvascular Endothelial Cells (HBMECs). Results: The results demonstrated that nano-flavonoids loaded with myricetin showed more evenly distributed targeting tissues and enhanced anti-tumor efficiency in vivo without significant cytotoxicity to Caco-2 cells and alteration in the Trans Epithelial Electric Resistance (TEER). There was no pathological evidence of renal, hepatic or other organs dysfunction after the administration of nanoflavonoids, which showed no significant influence on cytotoxicity to Caco-2 cells. Conclusion: In conclusion, Labrasol/F68-NMs loaded with MYR and quercetin could enhance antiglioma effect in vitro and in vivo, which may be better tools for medical therapy, while the pharmacokinetics and pharmacodynamics of nano-flavonoids may ensure optimal therapeutic benefits.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 427
Author(s):  
Amin Mirzaaghasi ◽  
Yunho Han ◽  
So-Hee Ahn ◽  
Chulhee Choi ◽  
Ji-Ho Park

Exosomes have attracted considerable attention as drug delivery vehicles because their biological properties can be utilized for selective delivery of therapeutic cargoes to disease sites. In this context, analysis of the in vivo behaviors of exosomes in a diseased state is required to maximize their therapeutic potential as drug delivery vehicles. In this study, we investigated biodistribution and pharmacokinetics of HEK293T cell-derived exosomes and PEGylated liposomes, their synthetic counterparts, into healthy and sepsis mice. We found that biodistribution and pharmacokinetics of exosomes were significantly affected by pathophysiological conditions of sepsis compared to those of liposomes. In the sepsis mice, a substantial number of exosomes were found in the lung after intravenous injection, and their prolonged blood residence was observed due to the liver dysfunction. However, liposomes did not show such sepsis-specific effects significantly. These results demonstrate that exosome-based therapeutics can be developed to manage sepsis and septic shock by virtue of their sepsis-specific in vivo behaviors.


Sign in / Sign up

Export Citation Format

Share Document